Cipronat IV

Form: IV injection
Dosage: 200mg/100ml
Packaging: Bottle 100 ml

Injectable antibiotic belonging to the fluorochinolone class

Active substance: ciprofloxacin

Form: solution for IV infusion

Dosage: 200 mg/100 ml solution

 

Packaging:

Box containing: transparent glass bottle with 100 ml infusion solution corresponding to 200 mg ciprofloxacin

 

Target: patients (adults and children) who require treatment with ciprofloxacin injection

Cipronat 200 mg/100 ml IV solution is indicated for the treatment of infections caused by bacteria sensitive to ciprofloxacin

  • Urinary and genital infections including infections due to Neisseria gonorrhoeae.

– Uretritis and cervicitis

– Gonorrhea (gonorrhoea)

– Orchi-epididymitis

  • Chronic bacterial prostatitis
  • Gastrointestinal and intra-abdominal infections (bacterial enteritis – traveller’s diarrhoea – typhoid fever)
  • Skin and skin structure infections (Gram-negative bacteria)
  • Bone and joint infections (Gram negative)
  • Prophylaxis of meningitis (invasive Neisseria meningitidis infections)
  • Systemic Infection Inhalation anthrax (Gram negative)

Upper and lower respiratory infections (Ciprofloxacin is not the first choice for upper and lower respiratory infections)

– Acute sinusitis (due to Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis)

– Chronic purulent otitis media. Acute exacerbation of chronic sinusitis, especially due to Gram-negative bacteria.

– External malignant otitis

– exacerbations of chronic obstructive pulmonary disease, bronchopulmonary infections in cystic fibrosis or bronchiectasis, pneumonia.

Exception: Bronchopulmonary infections in cystic fibrosis, due to Pseudomonas aeruginosa.

CipronatĀ® 200 is given intravenously and administered by your doctor or nurse.

The usual dose for adults is 200-400 mg, twice daily.

For treating a pulmonary exacerbation in patients aged 5-17 with cystic fibrosis, where the benefit is considered to outweigh the risks, the dose is 10 mg/kg IV every 8 hours (the maximum daily dose is 1200 mg). The infusion should be administered over 60 minutes.

Cipronat IV is administered as an intravenous infusion. The posology depends on

  • the indication
  • the severity and location of the infection
  • the sensitivity of the pathogen(s) responsible
  • the renal function of the patient
  • and in children and adolescents the body weight.

The duration of treatment depends on the severity of the disease and the clinical and bacteriological evolution.

After initiating intravenous treatment, oral treatment (Cipronat tablets) may be considered depending on the clinical context and the physician’s opinion.

In case of severe impairment or if the patient is unable to swallow the tablets (e.g. tube-fed patients), it is recommended to start treatment with intravenous ciprofloxacin until oral retreatment is possible.

Adults: Daily dosage is usually 400 mg (2 vials) 2 to 3 times daily

Children: Daily dosage is usually 10mg/kg 3 times daily with a maximum of 400mg per dose

Please refer to the SMPC for details on dosage and duration of treatment

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma